Past CureTalks
Inherited Gene Mutations in Myeloma and Role of Precision Medicine
Multiple Myeloma is the second most common cancer of the blood and is largely incurable. A recent study has found that a specific gene mutation can increase the risk of developing myeloma six to nine fold. The lead author of…
Alzheimer’s or Dementia. What’s the Difference?
Over 10 million people in the US have a neurodegenerative condition. Half of these people have Alzheimer's Disease making it the most common neurodegenerative condition in the US. Among the remaining, a large population suffer from frontotemporal dementia (FTD). However,…
Latest Advances in Myeloma Treatment: ASCO and EHA 2018 Highlights
The treatment field of Multiple Myeloma continues to move forward as novel agents and treatment combinations expand. Whether you are standard risk patient or belong to high-risk group, treatment paradigms are getting better. We are talking to Dr. Mateos on…
Reversing Blindness with New FDA Approved Retinal Gene Therapy
In December 2017, the FDA approved a DNA altering medication that can reverse an inherited form of progressive blindness. Luxturna is a gene therapy which can treat a condition called Leber's Congenital Amaurosis (LCA) wherein people have inherited two faulty…
Multiple Myeloma: An Insight into Early Intervention and Personalized Therapies
Myeloma patients are definitely living longer. A decade ago the median survival was 3 to 4 years, while now it is in the range of 8 to 10 years. With all the new drugs and treatments that have been approved,…